STOCK TITAN
  1. Home
  2. News
  3. BTTX

Better Therapeutics Inc - BTTX STOCK NEWS

Welcome to our dedicated news page for Better Therapeutics (Ticker: BTTX), a resource for investors and traders seeking the latest updates and insights on Better Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Better Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Better Therapeutics's position in the market.

News
Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq
Rhea-AI Summary
Better Therapeutics, Inc. (BTTX) announced the termination of employees and exploration of strategic alternatives, including potential wind-down. The Company faces delisting from Nasdaq unless compliance is regained. Safe Harbor Statement included.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-82.84%
Tags
none
-
News
Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers
Rhea-AI Summary
Better Therapeutics (BTTX) partners with ACLM to offer one million prescriptions of AspyreRx to underserved communities affected by type 2 diabetes, aiming to improve diabetes outcomes in the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.26%
Tags
partnership
-
News
Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
Rhea-AI Summary
Better Therapeutics, Inc. (BTTX) is set to present 180-day outcomes data at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in March 2024. The company will showcase the effectiveness of AspyreRx™ in treating type 2 diabetes, demonstrating significant improvements in various health parameters. Moreover, Better Therapeutics will host an educational session to discuss the benefits of AspyreRx and its combination with glucagon-like peptide 1 (GLP-1) agonists.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.78%
Tags
none
News
Better Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Rhea-AI Summary
RedChip Companies will air interviews with Better Therapeutics, Inc. (Nasdaq:BTTX) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show on Bloomberg TV. Better Therapeutics offers a groundbreaking approach to managing cardiometabolic diseases with its FDA-authorized product AspyreRx™, showcasing significant outcomes in treating type 2 diabetes. Biotricity revolutionizes cardiac care with remote diagnostic solutions, capturing an 8% market share in cardiology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.5%
Tags
none
-
News
Better Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease
Rhea-AI Summary
Better Therapeutics (BTTX) receives FDA Breakthrough Device Designation for its novel Cognitive Behavioral Therapy platform to potentially treat metabolic dysfunction-associated steatohepatitis, showcasing promising clinical study results and paving the way for strategic partnerships.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.37%
Tags
none
-
News
Better Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes Treatment
Rhea-AI Summary
Better Therapeutics Inc. (NASDAQ: BTTX) has entered into a rebate agreement with a leading Pharmacy Benefit Manager, effective January 1, 2024, providing plan participants the ability to add AspyreRx™ to their formularies with rebate eligibility. This agreement opens up an important pathway for access to treatment for millions of patients with type 2 diabetes, demonstrating recognition of the value proposition of innovative solutions like AspyreRx and representing an important step toward increasing accessibility and coverage of the product for patients in need.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.26%
Tags
none
News
Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone
Rhea-AI Summary
Better Therapeutics Inc. (NASDAQ: BTTX) has announced the publication of health economic data for its prescription-only digital behavioral treatment for type 2 diabetes (T2D), AspyreRx. The study found that AspyreRx plus standard of care was estimated to be superior to SoC alone, providing more life years and improvements in quality of life at a lower cost. From a healthcare payer perspective, AspyreRx plus SoC was dominant, with gains in quality-adjusted life years (QALYs) and cost savings of $7,343 per patient over the lifetime horizon. The study supports the potential efficacy and economic viability of digital therapeutics, recognizing the cost-effectiveness of integrating digital therapeutics into mainstream clinical practice. The estimated national cost of diabetes in 2022 was $412.9 billion, making the publication of this data crucial in driving sustainable solutions that can benefit both patients and the overall healthcare system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.65%
Tags
none
-
News
Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States
Rhea-AI Summary
Better Therapeutics Inc. (BTTX) and Glooko, Inc. have announced a partnership to integrate Better Therapeutics’ AspyreRx™ digital behavioral treatment for type 2 diabetes (T2D) into Glooko’s diabetes management platform. This collaboration aims to enable healthcare providers in the United States to identify suitable patients for AspyreRx, facilitate prescriptions, and track patients throughout their treatment. Glooko’s solutions have aided over 3.4 million people with diabetes in the U.S. and are utilized in nearly 5,000 clinic locations.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.92%
Tags
partnership
-
News
Better Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease
Rhea-AI Summary
Better Therapeutics, Inc. (NASDAQ: BTTX) has requested Breakthrough Device Designation from the FDA for its prescription digital therapeutics to treat MASLD and MASH, conditions affecting millions of Americans with no approved treatments. The request follows the successful LivVita Liver Study, showing promising results in reducing liver fat and improving liver health. The company's fiscal year 2023 ended with $4.2 million in cash and cash equivalents.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.15%
Tags
none
News
Better Therapeutics Strengthens Financial Position Through Amendment to Debt Facility and Implementation of Cost Reductions
Rhea-AI Summary
Better Therapeutics, Inc. (BTTX) extends cash runway to demonstrate commercial traction with AspyreRx in Type 2 Diabetes. The company negotiated an amendment to its debt facility, implemented cost-saving measures, and expects to improve its financial position by approximately $5 million through the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.7%
Tags
none
Stock BTTX logo
Better Therapeutics Inc

Nasdaq:BTTX

BTTX Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

BTTX Stock Data

648.74k
21.11M
53.34%
2.95%
3.9%
Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Professional, Scientific, and Technical Services
Link
United States
San Francisco

About BTTX

better therapeutics (f/k/a farewell) is developing prescription digital therapeutics for treating chronic disease. its innovative solution combines software, human coaching augmented by artificial intelligence, and advanced analytics to address the behaviors at the root cause of most chronic conditions, in a manner that can scale rapidly to address millions of covered lives. better’s digital therapeutics are based on well-established evidence, fit within existing clinical treatment guidelines, and can be used with or without other interventions. better believes non-drug treatment options are essential to reducing the unnecessary health and cost burden of chronic disease on individuals, payers, and the nation.